Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial

IMPORTANCE: Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. OBJECTIVE: To investigate the combination of everolimus plus endocrine therapy in first-line and se...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Royce, Melanie, Bachelot, Thomas, Villanueva, Cristian, Özgüroğlu, Mustafa, Azevedo, Sergio J., Cruz, Felipe Melo, Debled, Marc, Hegg, Roberto, Toyama, Tatsuya, Falkson, Carla, Jeong, Joon, Srimuninnimit, Vichien, Gradishar, William J., Arce, Christina, Ridolfi, Antonia, Lin, Chinjune, Cardoso, Fatima
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885212/
https://ncbi.nlm.nih.gov/pubmed/29566104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0060
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares